Potent and selective aromatase inhibitor: in vitro and in vivo studies with s-triazine derivative sef19

References

• Lonning P E, Kvinnsland S, Thorsen T, Ueland P M. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clin Pharmacokinet 1987; 13: 393–406
   PubMed Web of Science ®Google Scholar
• Dexter R N, Fishman L M, Ney R L, Liddle G W. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: Studies of the mechanism of action. J Clin Endocr 1967; 27: 473–480
   PubMed Web of Science ®Google Scholar
• Cohen M P. Aminoglutethimide inhibition of adrenal desmolase activity. Proc Soc Exper Biol Med 1968; 127: 1086–1900
   PubMedGoogle Scholar
• Gower D B. Modifiers of steroid-hormone metabolism: A review of their chemistry biochemistry and clinical application. J Steroid Biochem 1974; 5: 501–523
   PubMedGoogle Scholar
• Santen R J. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Res Treat 1981; 1: 183–202
   PubMedGoogle Scholar
• Dowsett M, Goss P E, Powles T J, Hutchinson G, Brodie AM H, Jeffcoate S L, Coombes R C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 1987; 47: 1957–1961
   PubMed Web of Science ®Google Scholar
• Cunningham D, Powles T J, Dowsett M, Hutchinson G, Brodie AM H, Ford H T, Gazet J-C, Coombes R C. Oral 4-hydroxyandrostenedione a new endocrine treatment for disseminated breast cancer. Cancer Chemother Pharmacol 1987; 20: 253–255
   PubMed Web of Science ®Google Scholar
• Iino Y, Sugamata N, Susumu N, Owada S, Tago T, Sato H, Yokoe T, Maemura M, Morishita Y, Horiuchi R. Antitumor effects of a nonsteroidal aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[α]anthracene-induced mammary tumors in rats. Jpn J Clin Oacol 1991; 21: 153–159
   PubMedGoogle Scholar
• Schieweck K, Bhatnagar A S, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Molec Biol 1993; 44: 633–636
   PubMed Web of Science ®Google Scholar
• Lipton A, Harvey H A, Demers L M, Hanagan J R, Mulagha M T, Kochak G M, Fitzsimmons S, Sanders S I, Santen R J. A phase I trial of CGS 16949A. Cancer 1990; 65: 1279–1285
   PubMedGoogle Scholar
• Raats J I, Falkson G, Falkson H C. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 1992; 10: 111–116
   PubMed Web of Science ®Google Scholar
• Brodie AM H. Aromatase inhibitors in the treatment of breast cancer. J Steroid Biochem Molec Biol 1994; 49: 281–287
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smithers D, Moore J, Trunet P F, Coombes R C, Powles T J, Rubens R, Smith I E. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur J Cancer 1994; 30A: 453–1458
   PubMedGoogle Scholar
• Tanino H, Kubota T, Yamada Y, Koh J, Takeuchi T, Kase S, Furuawa T, Takahashi M, Fukuda S, Ogose N, Komatsu T, Sakato M, Kitajima M, Sakurai T, Naito Y, Hoffman R M. A newly developed haxamethymelamine derivative SAE9 with both antitumor and aromatase-inhibitory activity. Anticancer Res 1993; 13: 623–626
   PubMedGoogle Scholar
• Matsuno T, Kato M, Tsuchida Y, Takahashi M, Yaguchi S, Terada S. Synthesis of imidazolyl-1,3,5-triazine derivatives and their aromatase inhibitory activity. Chem Pharmac Bull 1996, In press
   Google Scholar
• Yuan P-M, Nakajin S, Haniu M, Shinoda M, Hall P F, Shively J E. Steroid 21-hydroxylase (cytochrome P-450) from porcine adrenocortical microsomes: Microsequence analysis of cysteine-containing peptides. Biochemistry 1983; 22: 143–149
   PubMed Web of Science ®Google Scholar
• Kimura T. Biochemical aspect of iron-sulfur linkage in non-heme iron protein, with special reference to “adrenodoxin”. Structure and Bonding, vol. 5, J B Neilands, R S Nyholm, D Reinen, RJ P Williams. Springer-Verlag, Berlin 1968; pp. 1–40
   Google Scholar
• Thompson E A, Jr., Thompson SP K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974; 249: 5364–5372
   PubMed Web of Science ®Google Scholar
• Numazawa M, Mutsumi A, Asano N, Ito Y. A time-dependent inactivation of aromatase by 19-substituted androst-4-ene-3,6,17-triones. Steroids 1993; 58: 40–46
   PubMedGoogle Scholar
• Shikita M, Hall P F. The Stoichiometry of the conversion of cholesterol and hydroxycholesterols to pregnenolone (3β-hydroxypregn-5-en-20-one) catalyzed by adrenal cytochrome P-450. Proc Natl Acad Sci U.S.A 1974; 71: 1441–1445
   PubMedGoogle Scholar
• Nakajin S, Hall P F. Microsomal cytochrome P-450 from neonatal pig testis. J Biol Chem 1981; 256: 3871–3876
   PubMed Web of Science ®Google Scholar
• Shizuta Y, Kawano T, Mitsuuci Y, Toda K, Miyahara K, Ichikawa Y, Imura H, Ulick S. Molecular genetic studies on the biosynthesis of aldosterone in humans. J Steroid Biochem Molec Biol 1992; 43: 981–987
   PubMedGoogle Scholar
• Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Sakoda M, Hiromi K. Determination of the best-fit values of kinetic parameters of the Michaelis-Menten equation by the method of least squares with the Taylor expansion. J Biochem 1976; 80: 547–555
   PubMedGoogle Scholar
• Nakajin S, Hall P F. Purification to homogeneity of aromatase from human placenta. Biochem Biophys Res Commun 1986; 134: 704–710
   PubMed Web of Science ®Google Scholar
• Meyer A S. Conversion of 19-hydroxy-Δ4-androstene-3,17-dione to estrone by endocrine tissue. Biochim Biophys Acta 1955; 17: 441–442
   PubMedGoogle Scholar
• Santen R J, Samojlik E, Demers L, Badder E. Adrenal of male dog secretes androgens and estrogens. Am J Physiol 1980; 239: E109–E112
   Google Scholar
• Lamberts SW J, Bruining H A, Marzouk H, Zuiderwijk J, Uitterlinden P, Blijd J J, Hackeng WH L, deJong F H. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J Clin Endocrinol Metab 1989; 69: 896–901
   PubMed Web of Science ®Google Scholar
• Santen R J, Demers L M, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab 1989; 68: 99–106
   PubMed Web of Science ®Google Scholar
• Dowsett M, Stein R C, Mehta A, Coombes R C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocr 1990; 32: 623–634
   PubMed Web of Science ®Google Scholar
• Hausler A, Monnet G, Borer C, Bhatnagar A S. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal. J Steroid Biochem 1989; 34: 567–570
   PubMedGoogle Scholar
• Steel R E, Mellor L B, Sawyer W K, Wasvary J M, Browne L J. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids 1987; 50: 147–161
   PubMedGoogle Scholar
• Bhatnagar A S, Häusler A, Schieweck K. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors. J Enz Inhibit 1990; 4: 179–186
   PubMedGoogle Scholar
• Selvaraj N, Shetty G, Vijayalakshmi K, Bhatnagar A S, Moudgal N R. Effect of blocking oestrogen synthesis with a new generation aromatase inhibitor CGS 16949A on follicular maturation induced by pregnant mare serum gonadotrophin in the immature rat. J Endocr 1994; 142: 563–570
   PubMed Web of Science ®Google Scholar